Future watch
ABHI leads Chief Innovation Officer call In 2017, ABHI, working with the Nuffield Trust, set out to investigate why the NHS struggles to make the most of new innovations.
O
f the findings, one of the biggest barriers to adopting innovation is that too often it is not embedded in routine processes and operational management decisions. It is frequently seen as a luxury, only to be attempted when everything else is going well rather than as a core part of improving quality and efficiency. NHS Trust Boards see regular metrics on finance and performance, quality and safety, and workforce, with Executive Directors responsible for these important areas. As part of their “Well Led� inspection framework, NHS organisations are required to have robust systems and processes in place for learning, continuous improvement and
innovation. But, with few exceptions, nobody at a Board level holds this portfolio. Until this is actively built into a senior job description, it is unlikely to become business as usual.
hospitals to deliver efficiencies whilst adopting life changing HealthTech. As part of each hospital Board, Chief Innovation Officers can make a fundamental difference to the NHS, whilst ensuring maximum value to the taxpayer.
To find out more, contact eleanor.charsley@abhi.org.uk
This is why ABHI is calling on every NHS organisation to appoint a dedicated Chief Innovation Officer whose role will enable
www.abhi.org.uk
We innovate healthcare At Roche our aim is to improve the health, quality of life and well-being of people around the world by providing an innovative range of diagnostic solutions and medicines. Roche is a global, research-focused healthcare company with Group Headquarters in Basel, Switzerland. Our strategy is clear - the patient lies at the heart of everything we do and our focus is fitting the treatment to the patient through prescription pharmaceuticals and in-vitro diagnostics. What makes Roche distinctive is our pursuit of excellence in science as we deliver the best solutions for healthcare professionals and improve patient outcomes; this is achieved through our unique combination of Pharmaceuticals and Diagnostics. Everyday, our products help patients and the healthcare professionals who care for them by detecting, preventing, diagnosing, treating and monitoring diseases. We are proud to have played a pioneering role in UK healthcare since 1908. Today, we are the leading in-vitro diagnostics company in the UK and the leading provider of pharmaceutical treatments for cancer and viral diseases. We are also a major supplier of medicines for the treatment of transplantation, virology, bone and rheumatology and renal anaemia. In total, our UK pharmaceutical and diagnostics businesses employ nearly 2,000 people.
Personalised Healthcare We combine our strengths in pharmaceuticals and diagnostics to better fit treatments to patients. When genetic differences can be identified, the efficacy and safety of medicines can be improved enormously. To this end we have a companion diagnostic strategy for every molecule we develop.
Diagnostics As the UK leader in diagnostics solutions, we offer a uniquely broad and innovative portfolio of products to patients, physicians, researchers, hospitals, laboratories and universities. Our UK Diagnostics business, headquartered in Burgess Hill, West Sussex, employs approximately 500 highly skilled individuals. Diagnostics is set to play an increasingly important role in the future of healthcare as genetic knowledge presents new and exciting opportunities. Our desire is to provide clinicians and patients with Actionable Health Information - information that reduces the uncertainty in the medical decision making process, enabling them to choose between available alternatives to prevent or treat disease.
Tel: +44 (0)1444 256000 www.roche.co.uk At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives For daily lifescience news visit www.lifescienceindustrynews.com 17
